NBIX · Neurocrine Biosciences
413 filings
NBIX SEC Filings
Neurocrine Biosciences - 413 total filings
NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.
- 8-K · Feb 5, 2016
- 10-K · Feb 11, 2016
- 8-K · Feb 11, 2016
- 10-K/A · Apr 29, 2016
- 10-Q · May 5, 2016
- 8-K · May 5, 2016
- 8-K · May 24, 2016
- 8-K · Aug 3, 2016
- 10-Q · Aug 3, 2016
- 8-K · Sep 23, 2016
- 8-K · Oct 11, 2016
- 10-Q · Nov 2, 2016
- 8-K · Nov 2, 2016
- 8-K · Dec 23, 2016
- 8-K · Jan 6, 2017
- 8-K · Feb 10, 2017
- 10-K · Feb 14, 2017
- 8-K · Feb 14, 2017
- 8-K · Mar 13, 2017
- 8-K · Apr 12, 2017
- 8-K · Apr 25, 2017
- 8-K · May 2, 2017
- 10-Q · May 9, 2017
- 8-K · May 9, 2017
- 8-K · May 24, 2017
- 8-K · Jun 9, 2017
- 8-K · Jul 5, 2017
- 8-K · Jul 12, 2017
- 10-Q · Aug 3, 2017
- 8-K · Aug 3, 2017
- 8-K/A · Sep 7, 2017
- 8-K · Oct 5, 2017
- 8-K · Oct 10, 2017
- 8-K · Oct 17, 2017
- 8-K · Oct 19, 2017
- 10-Q · Nov 1, 2017
- 8-K · Nov 1, 2017
- 8-K · Dec 5, 2017
- 8-K · Jan 8, 2018
- 8-K · Feb 9, 2018
- 10-K · Feb 13, 2018
- 8-K · Feb 13, 2018
- 8-K · Feb 14, 2018
- 8-K · Apr 30, 2018
- 10-Q · Apr 30, 2018
- 8-K · May 30, 2018
- 8-K · Jul 24, 2018
- 10-Q · Jul 31, 2018
- 8-K · Jul 31, 2018
- 8-K · Aug 3, 2018
- 8-K · Sep 24, 2018
- 8-K · Nov 5, 2018
- 10-Q · Nov 5, 2018
- 8-K · Dec 12, 2018
- 8-K · Jan 7, 2019
- 8-K · Jan 29, 2019
- 8-K · Feb 5, 2019
- 10-K · Feb 8, 2019
- 8-K · Apr 26, 2019
- 10-Q · Apr 29, 2019
- 8-K · Apr 29, 2019
- 8-K · May 23, 2019
- 8-K · Jul 29, 2019
- 10-Q · Jul 29, 2019
- 8-K · Sep 11, 2019
- 10-Q · Nov 4, 2019
- 8-K · Nov 4, 2019
- 8-K · Jan 13, 2020
- 8-K · Feb 4, 2020
- 8-K · Feb 5, 2020
- 10-K · Feb 7, 2020
- 8-K · Apr 9, 2020
- 8-K · May 6, 2020
- 10-Q · May 6, 2020
- 8-K · May 21, 2020
- 8-K · Jun 16, 2020
- 8-K · Jul 13, 2020
- 8-K · Jul 28, 2020
- 8-K · Aug 3, 2020
- 10-Q · Aug 3, 2020
- 8-K · Aug 28, 2020
- 8-K · Sep 10, 2020
- 10-Q · Nov 9, 2020
- 8-K · Nov 9, 2020
- 8-K · Nov 19, 2020
- 8-K · Nov 24, 2020
- 8-K · Jan 8, 2021
- 8-K · Feb 2, 2021
- 8-K · Feb 4, 2021
- 10-K · Feb 5, 2021
- 8-K · Apr 16, 2021
- 10-Q · May 5, 2021
- 8-K · May 5, 2021
- 8-K · May 21, 2021
- 10-Q · Aug 3, 2021
- 8-K · Aug 3, 2021
- 10-Q · Nov 1, 2021
- 8-K · Nov 1, 2021
- 8-K · Nov 22, 2021
- 8-K · Dec 23, 2021
- 8-K · Jan 6, 2022
- 8-K · Feb 11, 2022
- 10-K · Feb 11, 2022
- 8-K · May 4, 2022
- 10-Q · May 4, 2022
- 8-K · May 23, 2022
- 8-K · May 25, 2022
- 8-K · Jun 1, 2022
- 10-Q · Aug 4, 2022
- 8-K · Aug 4, 2022
- 8-K · Aug 30, 2022
- 8-K · Nov 1, 2022
- 10-Q · Nov 1, 2022
- 8-K · Jan 9, 2023
- 8-K · Feb 6, 2023
- 10-K · Feb 9, 2023
- 8-K · Feb 10, 2023
- 8-K · Feb 24, 2023
- 8-K · Mar 29, 2023
- 10-Q · May 3, 2023
- 8-K · May 3, 2023
- 8-K · May 19, 2023
- 8-K · Jul 12, 2023
- 8-K · Jul 13, 2023
- 8-K · Aug 1, 2023
- 10-Q · Aug 1, 2023
- 8-K · Sep 12, 2023
- 8-K · Oct 5, 2023
- 8-K · Oct 6, 2023
- 8-K · Oct 31, 2023
- 10-Q · Oct 31, 2023
- 8-K · Nov 9, 2023
- 8-K · Nov 13, 2023
- 8-K · Feb 7, 2024
- 10-K · Feb 9, 2024
- 10-Q · May 1, 2024
- 8-K · May 1, 2024
- 8-K · May 23, 2024
- 8-K · May 28, 2024
- 10-Q · Aug 1, 2024
- 8-K · Aug 1, 2024
- 8-K · Aug 28, 2024
- 8-K · Oct 11, 2024
- 10-Q · Oct 30, 2024
- 8-K · Oct 30, 2024
- 8-K · Nov 1, 2024
- 8-K · Dec 20, 2024
- 8-K · Jan 27, 2025
- 8-K · Feb 6, 2025
- 10-K · Feb 10, 2025
- 8-K · Apr 4, 2025
- 8-K · May 5, 2025
- 10-Q · May 5, 2025
- 8-K · May 22, 2025
- 8-K · May 30, 2025
- 10-Q · Jul 30, 2025
- 8-K · Jul 30, 2025
- 10-Q · Oct 28, 2025
- 8-K · Oct 28, 2025
- 8-K · Nov 24, 2025
- 8-K · Feb 11, 2026
- 10-K · Feb 11, 2026
- 8-K · Apr 6, 2026
- 10-Q · May 5, 2026
- 8-K · May 5, 2026
- 8-K · May 18, 2026
- 8-K · May 28, 2026
- 8-K · Jul 30, 2026
- 8-K/A · Jul 31, 2026
- 10-Q · Jul 31, 2026
- 8-K · Sep 28, 2026
- 8-K · Nov 2, 2026
- 10-Q · Nov 2, 2026
Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2026
Neurocrine Biosciences, Inc. reported third-quarter 2026 total revenues of $1,122.7 million, up from $794.9 million a year earlier, with net product sales of $1,119.0 million. Net income was $206.5 million, or $1.96 per diluted share, compared with $209.5 million, or $2.04 per diluted share, in the third quarter of 2025. For the first nine months of 2026, total revenues were $2,896.2 million and net income was $548.8 million, or $5.26 per diluted share. The period was shaped by the May 18, 2026 acquisition of Soleno Therapeutics, Inc., which added VYKAT XR. The preliminary consideration transferred was $2,829.9 million, including $2,762.5 million paid to Soleno stockholders, and the acquisition produced $2,191.0 million of net intangible assets and $500.6 million of goodwill. Soleno contributed $106.7 million of net revenues in the third quarter and $161.1 million from the acquisition date through September 30, 2026, and a net loss of $35.1 million over that later period. Product sales growth was driven by CRENESSITY, with third-quarter net sales of $210.8 million versus $98.1 million a year earlier, and by INGREZZA, with third-quarter net sales of $801.5 million versus $686.6 million. Operating expenses rose sharply, with research and development at $351.8 million and selling, general, and administrative expenses at $366.3 million in the quarter. Cash and cash equivalents were $641.5 million at September 30, 2026, and cash flows from operating activities were $677.4 million for the nine months. Cash, cash equivalents and marketable securities totaled $789.7 million, down from $2,543.4 million at December 31, 2025, reflecting the acquisition. The company borrowed and repaid $600.0 million under a new $1.0 billion revolving credit facility, and $1.0 billion of borrowing capacity was available at quarter end. The filing also discloses risks that investors should weigh. A Paragraph IV ANDA filing by Alvogen against VYKAT XR was received in September 2026, and the company sued in October 2026, which triggers a statutory 30-month stay of approval. The FDA identified fluid retention as a potential safety signal for VYKAT XR in a quarterly report published in September 2026. The Department of Justice is investigating INGREZZA sales and marketing, and a securities class action against Soleno is pending. The company repurchased $158.1 million of common stock in the first nine months, with $174.2 million remaining under its 2025 Repurchase Program.
Neurocrine Biosciences 8-K Report, Financial Results (Nov 2, 2026)
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported third-quarter 2026 financial results on November 2, 2026, with total revenues of $1,123 million, up 41% year-over-year from $795 million. INGREZZA net product sales were $801 million (up 17%), CRENESSITY net product sales were $211 million (up 115%), and VYKAT XR net product sales were $107 million. The company said net product sales exceeded $1 billion for the first time. GAAP net income was $207 million ($1.96 diluted EPS) versus $210 million ($2.04) a year earlier, while non-GAAP net income was $347 million ($3.29 diluted EPS) versus $222 million ($2.17). The company raised its full-year 2026 INGREZZA net product sales guidance to $2.90 to $2.925 billion from $2.825 to $2.875 billion. Updated full-year guidance also lowered GAAP SG&A to $1.540 to $1.560 billion from $1.575 to $1.600 billion, and raised IPR&D to $34 million from $23 million; GAAP R&D guidance was unchanged. Results reflect the May 2026 acquisition of Soleno Therapeutics, Inc., which added VYKAT XR and about $2.2 billion of related intellectual property. Cash, cash equivalents and marketable securities were approximately $790 million at September 30, 2026, compared with $2,543 million at December 31, 2025. Other developments include Phase 1 initiation for NBIP-'1968 (a GLP-1/GIP/glucagon triple agonist for obesity), a Phase 2 study of NBI-'567 for cognitive impairment in Alzheimer's disease, and the appointment of Eiry W. Roberts, M.D. as Chief Medical Officer. The company will host an R&D Day in New York on December 15, 2026. The filing furnishes the earnings release under Item 2.02, which is not deemed filed for purposes of Section 18 of the Exchange Act.
Neurocrine Biosciences 8-K Report, Executive Changes (Sep 28, 2026)
Neurocrine Biosciences, Inc. disclosed a leadership change in its executive team. Its Board of Directors appointed Eiry W. Roberts, M.D., as Chief Medical Officer, succeeding Sanjay Keswani, M.D., effective September 28, 2026. The filing states that Dr. Keswani and the Board mutually agreed that his service as Chief Medical Officer would terminate as of September 25, 2026. Dr. Keswani will be entitled to severance benefits under Section 4.1 of the Company's Executive Severance Plan, subject to the plan's terms. The Company will enter into an Amended and Restated Employment Agreement with Dr. Roberts, effective as of the transition date, which replaces his May 30, 2025 employment agreement, as amended on November 21, 2025. Under the new agreement, Dr. Roberts will receive an annual base salary of $825,000 and a target annual cash bonus equal to 60% of base pay for calendar year 2026. He will also receive equity grants under the 2025 Equity Incentive Plan with target grant values of approximately $625,000 in stock options, $250,000 in restricted stock units, and $375,000 in performance-vesting restricted stock units. The equity grants are scheduled to be made two business days after the Company files its first Form 10-Q following the transition date, provided he remains employed. Dr. Roberts' existing equity awards will remain outstanding and continue vesting under their terms. The summary in the filing is not the full agreement. The Company anticipates filing the complete Employment Agreement with its Quarterly Report on Form 10-Q for the quarter ending September 30, 2026. The filing also includes standard forward-looking statement cautions.
Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2026
Neurocrine Biosciences, Inc. reported second-quarter 2026 total revenues of $959.0 million, up from $687.5 million a year earlier, and net income of $144.4 million, or $1.39 per diluted share, versus $107.5 million and $1.06 in the prior-year quarter. For the first six months, total revenues were $1,773.5 million and net income was $342.3 million, or $3.30 per diluted share. Net product sales of INGREZZA ($716.5 million in the quarter), CRENESSITY ($183.5 million) and the newly acquired VYKAT XR ($54.3 million) drove the results. Selling, general and administrative expense rose to $439.7 million in the quarter, including $96.8 million of acquisition-related expenses for the six months. The most significant event in the period was the May 18, 2026 acquisition of Soleno Therapeutics, Inc. for $53.00 per share in cash, with preliminary total consideration of $2.83 billion and cash paid, net of cash acquired, of $2.36 billion. The purchase price allocation is preliminary, and the company recognized $2.24 billion of developed product rights for VYKAT XR, with goodwill of $494.6 million. Funding came from cash on hand and sales and maturities of available-for-sale debt securities, and the company also borrowed and then repaid $600.0 million under a new $1.0 billion senior secured revolving credit facility. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $481.7 million, down from $2,543.4 million at December 31, 2025, and working capital was $763.0 million. The filing also discloses a Department of Justice civil investigative demand from August 2025 concerning sales and marketing of INGREZZA, which the company is cooperating with, and a securities class action against Soleno that Neurocrine is exposed to as the acquirer. Remaining authorization under the 2025 share repurchase program was $266.3 million at June 30, 2026.
Neurocrine Biosciences 8-K/A Report, Exhibit Filing (Jul 31, 2026)
Neurocrine Biosciences, Inc. filed this Amendment No. 1 on Form 8-K/A to amend its May 18, 2026 Current Report, which reported the completion of its merger with Soleno Therapeutics, Inc. The amendment adds Soleno's audited consolidated financial statements for the year ended December 31, 2025 (Exhibit 99.1), its unaudited interim condensed consolidated financial statements for the three months ended March 31, 2026 (Exhibit 99.2), and unaudited pro forma condensed combined statements of income for the six months ended June 30, 2026 and the year ended December 31, 2025 (Exhibit 99.3). The filing states that it does not update any other item or discuss developments after the original report's filing date. The acquisition, completed on May 18, 2026 at a price of $53.00 per Soleno share in cash, added VYKAT XR (diazoxide choline), described as a first-in-class therapy for hyperphagia in Prader-Willi syndrome. The pro forma statements, prepared under the acquisition method with Neurocrine as the accounting acquirer, show pro forma total revenues of $1,907.5 million and net income of $294.0 million for the six months ended June 30, 2026, and total revenues of $3,050.9 million and net income of $324.5 million for 2025. Diluted pro forma earnings per share are $2.83 and $3.17, respectively. The statements exclude synergies and cost savings, and the company describes the fair value estimates as preliminary, with the purchase accounting to be finalized within one year of the closing date. Financing was provided through a May 14, 2026 credit agreement for a five-year, $1.0 billion senior secured revolving credit facility. The company drew $600.0 million on May 18, 2026 at an initial rate of 4.896% (Term SOFR plus 1.25%) and had repaid the full amount as of June 30, 2026. The filing also reports an estimated $2,237.8 million fair value for the VYKAT XR intangible asset, with a 16-year useful life, and a $168.2 million inventory fair value step-up.
Neurocrine Biosciences 8-K Report, Financial Results (Jul 30, 2026)
Neurocrine Biosciences, Inc. (NBIX) reported second-quarter 2026 total revenues of $959 million, up 39% year over year from $688 million. INGREZZA net product sales were $716 million (up 15%), CRENESSITY net product sales were $184 million (up 247% from $53 million), and VYKAT XR net product sales were $54 million, included from the May 18, 2026 closing of the Soleno Therapeutics acquisition. Unaudited pro forma total revenues including a full quarter of VYKAT XR were $998 million. GAAP net income was $144 million, or $1.39 per diluted share, compared with $108 million, or $1.06, a year earlier. Non-GAAP net income was $297 million, or $2.85 per diluted share, compared with $166 million, or $1.65. The company raised its full-year 2026 INGREZZA net product sales guidance to $2.825 billion to $2.875 billion, from $2.7 billion to $2.8 billion. It also raised GAAP R&D guidance to $1.275 billion to $1.325 billion and GAAP SG&A guidance to $1.575 billion to $1.600 billion, reflecting pipeline investment and commercial spending for the launches. The Soleno acquisition was completed in May 2026 at $53.00 per share in cash, a total equity value of $2.9 billion. Cash, cash equivalents and marketable securities totaled $482 million at June 30, 2026, down from $2,543 million at December 31, 2025. The company also entered a $1.0 billion senior secured revolving credit facility in May 2026, with the full $1.0 billion available at June 30, 2026. Management highlighted two Phase 3 readouts expected in 2027 for osavampator in major depressive disorder and direclidine in schizophrenia. The filing states that the press release is furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act.
Neurocrine Biosciences 8-K Report, Executive Changes (May 28, 2026)
Neurocrine Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on May 27, 2026, with 90,118,625 of 100,581,991 eligible shares (record date March 31, 2026) present in person or by proxy. Stockholders elected three Class III Directors to terms expiring at the 2029 Annual Meeting: Kevin C. Gorman, Ph.D. (76,228,063 votes for), Gary A. Lyons (75,278,705 votes for), and Johanna Mercier (74,671,942 votes for). Continuing directors are William H. Rastetter, Ph.D., George J. Morrow, Leslie V. Norwalk, and Christine A. Poon (Class I, term expiring 2027), and Kyle W. Gano, Ph.D., Richard F. Pops, Shalini Sharp, and Stephen A. Sherwin, M.D. (Class II, term expiring 2028). Stockholders also approved, on an advisory basis, the compensation paid to the company's named executive officers (78,993,894 for, 5,669,155 against, 103,231 abstentions). They approved the amendment of the 2025 Equity Incentive Plan (the "Amended 2025 Plan") with 79,131,622 votes for and 5,568,926 against. A summary of the Amended 2025 Plan's material terms appears in the definitive proxy statement filed April 15, 2026, which is incorporated by reference. Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 83,880,185 votes for and 6,170,483 against. This filing reports routine annual meeting outcomes, with no material change to officers or directors disclosed.
Neurocrine Biosciences 8-K Report, Material Agreement (May 18, 2026)
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) completed its acquisition of Soleno Therapeutics, Inc. on May 18, 2026, through a cash tender offer at $53.00 per share followed by a merger under Section 251(h) of the Delaware General Corporation Law, with Soleno becoming a direct, wholly owned subsidiary. As of the offer expiration at one minute after 11:59 p.m. Eastern time on May 15, 2026, 46,356,114 Soleno shares, representing approximately 88.9% of issued and outstanding shares, had been validly tendered, satisfying the minimum condition. The aggregate cash paid in the offer and merger was approximately $2.9 billion, plus fees and expenses, funded from Neurocrine's available cash on hand. Soleno's Soleno Options with exercise prices below the offer price, and Soleno RSU Awards, were cashed out, and Soleno's common stock is no longer listed on the Nasdaq Capital Market. The acquisition adds VYKAT XR (diazoxide choline) extended-release tablets, approved by the FDA on March 26, 2025, for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome, to Neurocrine's commercial portfolio alongside INGREZZA and CRENESSITY. Neurocrine describes the product as the first and only approved treatment for hyperphagia in Prader-Willi syndrome. The company also disclosed a new five-year, $1.0 billion senior secured revolving credit facility dated May 14, 2026, with JPMorgan Chase Bank, N.A. as administrative agent, under which it made an initial borrowing of $600.0 million on the closing date. The credit agreement includes a maximum total net leverage ratio of 3.75:1.00, which may increase to 4.25:1.00 for certain periods following material acquisitions, and a minimum consolidated interest coverage ratio of 2.00:1.00. Neurocrine granted a security interest in substantially all of its assets, and material domestic subsidiaries will be required to guarantee the obligations. The company has stated it will file the required acquired-business financial statements and pro forma financial information by amendment within 71 calendar days after the initial Form 8-K filing deadline.
Neurocrine Biosciences 8-K Report, Financial Results (May 5, 2026)
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported first-quarter 2026 financial results on May 5, 2026, with total revenues of $814.5 million, compared with $572.6 million in the prior-year period, a 42% increase. Net product sales were $811.0 million, representing 44% year-over-year growth. INGREZZA net product sales were $656.9 million (20% growth year-over-year), and CRENESSITY net product sales were $153.3 million, versus $14.5 million in the first quarter of 2025. GAAP net income was $197.9 million, or $1.91 per diluted share, compared with $7.9 million, or $0.08 per diluted share, a year earlier. Non-GAAP net income was $200.5 million, or $1.94 per diluted share, versus $71.5 million, or $0.70, in the prior-year period. The company reaffirmed its full-year 2026 INGREZZA net sales guidance of $2.7 billion to $2.8 billion. Full-year GAAP R&D guidance is $1.200 billion to $1.250 billion, and GAAP SG&A guidance is $1.375 billion to $1.400 billion. The guidance excludes post-close expenses from the pending acquisition of Soleno Therapeutics. Operating expenses rose on higher R&D tied to the osavampator and direclidine Phase 3 programs and on expanded commercial sales teams. Cash, cash equivalents, and marketable securities totaled $2,647.2 million at March 31, 2026. A key corporate development is the definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, a total equity value of $2.9 billion, with closing expected in the second quarter of 2026. The company also initiated a Phase 2 study of NBI-1117570 in schizophrenia and a Phase 1 study of NBIP-'2118, a potential obesity therapy. Investors should weigh the strong top-line growth and reaffirmed INGREZZA guidance against rising operating costs and the integration risks of the Soleno transaction.
Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2026
Neurocrine Biosciences, Inc. reported first-quarter 2026 net income of $197.9 million, or $1.91 per diluted share, compared with $7.9 million, or $0.08 per diluted share, in the first quarter of 2025. Total revenues rose to $814.5 million from $572.6 million, driven by net product sales of $811.0 million. INGREZZA net product sales were $656.9 million versus $545.2 million a year earlier, and CRENESSITY net product sales were $153.3 million versus $14.5 million. Operating income was $193.4 million, up from $23.6 million, and the period included a $28.6 million pre-tax gain on the January 2026 sale of Neurocrine Group Limited to Immedica Pharma AB for $63.2 million in cash. Liquidity remained substantial, with total cash, cash equivalents and marketable securities of $2,647.2 million at March 31, 2026, versus $2,543.4 million at December 31, 2025, and working capital of $1,604.4 million. Cash flow from operating activities was $145.8 million. The company repurchased 0.4 million shares for $56.0 million during the quarter and had $276.3 million remaining under its 2025 Repurchase Program. The most significant subsequent event is the pending acquisition of Soleno Therapeutics, Inc. for an equity value of approximately $2.9 billion, through a $53.00 per share cash tender offer commenced April 20, 2026. The Hart-Scott-Rodino waiting period expired April 27, 2026, and the company expects to fund the transaction with cash on hand and expects closing in the second quarter of 2026, subject to a tender of at least a majority of Soleno shares and other customary conditions. The filing also discloses an ongoing U.S. Department of Justice civil investigative demand related to INGREZZA sales and marketing, and patent litigation with Zydus over INGREZZA SPRINKLE.
Neurocrine Biosciences 8-K Report, Material Agreement (Apr 6, 2026)
On April 5, 2026, Neurocrine Biosciences, Inc. entered into an Agreement and Plan of Merger with Soleno Therapeutics, Inc. under which Neurocrine, through a wholly owned subsidiary, will commence a cash tender offer for all outstanding Soleno shares at $53.00 per share. The press release attached as Exhibit 99.1 describes a total transaction equity value of $2.9 billion, to be funded with cash on hand and a modest amount of pre-payable debt, with no financing condition. The transaction is expected to close within 90 days of the April 6, 2026 announcement, subject to customary conditions including the expiration or termination of the HSR Act waiting period. The offer price represents a premium of approximately 34% to Soleno's April 2, 2026 closing share price and 51% to its 30-day VWAP, according to the press release. The deal centers on VYKAT XR (diazoxide choline), which the filing describes as the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome. The press release states VYKAT XR generated $190 million in 2025 revenue, including $92 million in the fourth quarter. Neurocrine expects the acquisition to add a product to its existing commercial portfolio alongside INGREZZA ($2.51 billion in 2025 revenue) and CRENESSITY ($301 million in 2025 revenue), and to support revenue growth and diversification. The merger agreement includes a $95,250,000 termination fee payable by Soleno in specified circumstances, including to accept a superior proposal, and a $141,500,000 reverse termination fee payable by Neurocrine if the HSR or antitrust-related conditions are not satisfied at termination. Soleno's CEO and Chairman Anish Bhatnagar and former CFO James Mackaness signed Tender and Support Agreements covering approximately 1.01% of outstanding Shares as of April 5, 2026. Soleno's board recommends that stockholders tender their shares.
Neurocrine Biosciences 8-K Report, Financial Results (Feb 11, 2026)
Neurocrine Biosciences, Inc. reported fourth-quarter and full-year 2025 results on February 11, 2026, as detailed in Exhibit 99.1. Total net product sales were $798.3 million for the fourth quarter and $2.83 billion for the full year, reflecting year-over-year growth of 29% and 22%, respectively. INGREZZA net product sales were $657.5 million in the fourth quarter and $2.51 billion for the full year, up 7% and 9% year-over-year. CRENESSITY net product sales were $135.3 million in the fourth quarter and $301.2 million for the full year, with 431 and 2,048 total new patient enrollment start forms, respectively. Fourth-quarter GAAP net income was $153.7 million ($1.48 per diluted share), compared with $103.1 million ($1.00) a year earlier. Full-year GAAP net income was $478.6 million ($4.67 per diluted share). Non-GAAP diluted EPS was $1.88 for the fourth quarter and $6.39 for the full year. Cash, cash equivalents, and marketable securities totaled approximately $2.54 billion at December 31, 2025. For 2026, the company guided to INGREZZA net product sales of $2.7 to $2.8 billion, GAAP R&D expense of $1.200 to $1.250 billion, and GAAP SG&A expense of $1.375 to $1.400 billion. Management highlighted advancing Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia, along with the initiation of a Phase 2 study of NBI-1065890 in adults with tardive dyskinesia. Operating expense increases in 2025 reflected expanded R&D investment, incremental CRENESSITY launch spending, and upfront payments for early-stage development candidate licenses. The filing notes that the information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act. Investors should review the GAAP-to-non-GAAP reconciliations in the attached tables, since the company excludes items such as stock-based compensation, which totaled $126.9 million in SG&A and $91.0 million in R&D for the full year.
Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2025
Neurocrine Biosciences, Inc. reported total revenues of $2.86 billion for 2025, up from $2.36 billion in 2024, driven by net product sales of $2.83 billion. INGREZZA net product sales were $2.51 billion for 2025 versus $2.31 billion in 2024, and CRENESSITY, launched in December 2024, generated $301.2 million in its first full year. The company's net income rose to $478.6 million, or $4.67 per diluted share, from $341.3 million, or $3.29 per diluted share, in 2024. Operating income was $619.1 million, compared with $570.5 million a year earlier, while research and development spending increased to $1.02 billion from $731.1 million, reflecting Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia. The company ended 2025 with $2.54 billion in cash, cash equivalents and marketable securities, up from $1.82 billion, and generated $782.7 million in operating cash flow. It repurchased $167.7 million of stock during 2025 and had $332.3 million remaining under its 2025 repurchase program. Its sales force expansion for INGREZZA and CRENESSITY is expected to be completed by the end of the first quarter of 2026. Key risks disclosed include a civil investigative demand from the U.S. Department of Justice in August 2025 concerning INGREZZA sales and marketing, a Paragraph IV patent challenge from Zydus relating to INGREZZA SPRINKLE, customer concentration in which four customers represent over 90% of gross product sales, and Medicare drug pricing pressures under the Inflation Reduction Act. The company also disclosed that two Phase 3 valbenazine studies and a Phase 2 MDD study did not meet their primary endpoints in 2025.
Neurocrine Biosciences 8-K Report, Executive Changes (Nov 24, 2025)
Neurocrine Biosciences, Inc. (the "Company") filed this Current Report on Form 8-K to disclose an executive compensation and employment matter under Item 5.02. The filing states that Sanjay Keswani, M.D. succeeded Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025. In connection with that transition, the Company and Dr. Roberts entered into an Amended and Restated Employment Agreement effective June 2, 2025, under which Dr. Roberts serves as Strategic Advisor through December 31, 2025. On November 21, 2025, the Company entered into an amendment to that Amended Employment Agreement extending the term of employment for an additional 12-month period, expiring December 31, 2026. The filing describes this only briefly and refers readers to the full amendment, which is filed as Exhibit 10.1. For investors, this is a routine executive-transition disclosure with no financial results, dollar amounts, or operational metrics stated in the filing. Its main significance is governance-related: it confirms the leadership handoff in the Chief Medical Officer role and extends Dr. Roberts's continued involvement with the Company as a strategic advisor through the end of 2026.
Neurocrine Biosciences 8-K Report, Financial Results (Oct 28, 2025)
Neurocrine Biosciences, Inc. reported third-quarter 2025 financial results for the quarter ended September 30, 2025, in a press release attached as Exhibit 99.1 to this Form 8-K. Total revenues were $794.9 million, compared with $622.1 million in the third quarter of 2024. Net product sales were $789.9 million, with INGREZZA net product sales of $686.6 million and CRENESSITY net product sales of $98.1 million. GAAP net income was $209.5 million, or $2.04 per diluted share, versus $129.8 million, or $1.24 per diluted share, a year earlier. Non-GAAP net income was $222.1 million, or $2.17 per diluted share, compared with $189.2 million, or $1.81 per diluted share, in the prior-year quarter. GAAP R&D expense rose to $250.0 million from $195.0 million, and GAAP SG&A expense rose to $291.6 million from $234.3 million, reflecting investment in the osavampator and direclidine Phase 3 programs, CRENESSITY launch activities, and the INGREZZA sales team expansion. The company reaffirmed its full-year 2025 INGREZZA net product sales guidance of $2,500 million to $2,550 million and updated its GAAP R&D guidance to $1,000 million to $1,020 million and GAAP SG&A guidance to $1,140 million to $1,160 million. Cash, cash equivalents, and marketable securities totaled $2,113.3 million at September 30, 2025, up from $1,815.6 million at December 31, 2024. The press release also highlighted clinical and corporate developments, including the start of a second Phase 3 registrational trial for direclidine in schizophrenia, new Phase 2 SAVITRI data for osavampator in major depressive disorder, a planned expansion of the INGREZZA and CRENESSITY sales teams to be completed by the end of the first quarter of 2026, and an R&D Day scheduled for December 16, 2025.
Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2025
Neurocrine Biosciences, Inc. reported strong third-quarter 2025 results in its Form 10-Q. Total revenues for the three months ended September 30, 2025 were $794.9 million, up from $622.1 million a year earlier, and net income was $209.5 million, versus $129.8 million. For the first nine months, total revenues were $2.06 billion and net income was $324.9 million. Net product sales of INGREZZA were $686.6 million in the quarter and $1.86 billion year-to-date, while CRENESSITY, launched in December 2024, contributed $98.1 million in the quarter and $165.8 million year-to-date. The company attributed the growth to strong patient demand for INGREZZA, partially offset by lower net price from new market access investments, and to CRENESSITY's launch. Operating expenses rose as the company invested in its commercial organization and pipeline. Research and development expense was $250.0 million in the quarter versus $195.0 million, driven by Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia. Selling, general, and administrative expense was $291.6 million versus $234.3 million. Cash, cash equivalents and marketable securities totaled $2.11 billion at September 30, 2025, and cash flow from operations was $394.3 million for the nine months. The company repurchased $167.7 million of stock in the first nine months under its 2025 program, with $332.3 million remaining. The filing also flags legal and regulatory matters that investors should monitor. These include patent litigation against Zydus over a generic version of INGREZZA SPRINKLE, a civil investigative demand from the U.S. Department of Justice in August 2025 related to INGREZZA sales and marketing, and an FDA untitled letter regarding INGREZZA promotional claims. The filing also notes a Phase 3 study of valbenazine for adjunctive schizophrenia treatment did not meet its primary endpoint, and that customer concentration is high, with four customers representing over 90% of gross product sales.
Neurocrine Biosciences 8-K Report, Financial Results (Jul 30, 2025)
Neurocrine Biosciences, Inc. reported second-quarter 2025 results for the period ended June 30, 2025, with total net product sales of $682 million, which the company describes as 17% year-over-year growth. INGREZZA net product sales were $624 million, up 15% sequentially from the first quarter and 8% year-over-year, and the company said the return to volume growth was driven by strong patient demand and a quarterly record in new prescriptions. CRENESSITY, the company's newer product, generated $53 million in net product sales, with 664 new patient enrollment start forms in the quarter and 76% reimbursement coverage for dispensed scripts. Total revenues were $687.5 million. GAAP net income was $107.5 million, or $1.06 per diluted share, versus $65.0 million, or $0.63 per diluted share, a year earlier. Non-GAAP net income was $166.2 million, or $1.65 per diluted share, compared with $168.9 million, or $1.63, in the prior-year quarter. The company narrowed its 2025 INGREZZA net product sales guidance to $2.5 billion to $2.55 billion, down from $2.5 billion to $2.6 billion, citing double-digit volume growth partially offset by lower net price from expanded access. It also updated full-year GAAP R&D expense guidance to $960 million to $1.01 billion and GAAP SG&A expense guidance to $1.135 billion to $1.155 billion. R&D guidance includes $60 million of development milestone expense tied to collaborations with Takeda and Nxera. Pipeline news was mixed. A Phase 3 study of adjunctive valbenazine in schizophrenia did not meet its primary endpoint, although the company cited consistent trends and a statistically significant effect in the PANSS positive symptom domain. The company initiated a Phase 3 registrational program for NBI-'568, an oral M4 selective muscarinic agonist, in schizophrenia, and began a Phase 1 study of NBIP-1435 for congenital adrenal hyperplasia. Cash, cash equivalents, and marketable securities totaled $1.85 billion at June 30, 2025, and $332 million remained under a $500 million share repurchase program.
Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2025
Neurocrine Biosciences, Inc. reported second-quarter 2025 results in this Form 10-Q for the quarter ended June 30, 2025. Total revenues were $687.5 million for the three months ended June 30, 2025, up from $590.2 million a year earlier, driven by net product sales of INGREZZA ($624.4 million) and the newly launched CRENESSITY ($53.2 million). Net income was $107.5 million, or $1.06 per diluted share, compared with $65.0 million, or $0.63 per diluted share, in the prior-year quarter. For the six months ended June 30, 2025, total revenues were $1,260.1 million and net income was $115.4 million, compared with $1,105.5 million and $108.4 million in the first half of 2024. Research and development expense rose to $244.3 million in the quarter from $191.1 million, reflecting Phase 3 programs for osavampator in major depressive disorder and NBI-1117568 in schizophrenia, and selling, general and administrative expense rose to $286.3 million from $242.0 million. As of June 30, 2025, the company reported total cash, cash equivalents and marketable securities of $1,849.4 million, compared with $1,815.6 million at December 31, 2024. Cash flows from operating activities were $166.8 million for the first six months of 2025, versus $194.9 million a year earlier. During the first six months, the company repurchased $167.7 million of common stock under its 2025 Repurchase Program, leaving $332.3 million available. Management stated that existing capital resources and anticipated product sales are expected to fund operations for at least the next 12 months. The filing also highlights litigation with Zydus over a generic version of INGREZZA SPRINKLE, filed after a Paragraph IV certification in March 2025, and notes that the One Big Beautiful Bill Act, signed July 4, 2025, will be reflected in the third-quarter report as the company continues evaluating its effects.
Neurocrine Biosciences 8-K Report, Executive Changes (May 30, 2025)
Neurocrine Biosciences, Inc. filed this Current Report on Form 8-K to disclose a leadership transition in its medical function and related compensatory arrangements. Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025. Dr. Roberts has served as Chief Medical Officer for the past seven years and will remain with the Company in a strategic advisory role following Dr. Keswani's succession. In connection with the transition, the Company entered into an Amended and Restated Employment Agreement with Dr. Roberts on May 30, 2025, effective upon the later of June 2, 2025 and the date the new Chief Medical Officer commences employment. The agreement amends and restates her employment agreement dated February 7, 2025. Under the amended agreement, Dr. Roberts will serve as Strategic Advisor to the CEO from the transition date through December 31, 2025, with an annual base salary of $731,400 and a target annual cash incentive bonus equal to 60% of base pay earned for calendar year 2025. The agreement also provides substantially the same severance benefits she was previously eligible for under the Company's Executive Severance Plan adopted February 7, 2025, and her outstanding equity awards will remain outstanding and continue to vest according to their terms. The filing is primarily an executive-transition disclosure and does not indicate any change to the Company's financial results or guidance.
Neurocrine Biosciences 8-K Report, Executive Changes (May 22, 2025)
Neurocrine Biosciences, Inc. reported in this Form 8-K, filed May 22, 2025, the results of its 2025 Annual Meeting of Stockholders, held May 21, 2025. The record date was March 24, 2025, when 98,938,234 shares of common stock were entitled to vote. Holders of 90,434,193 shares were present in person or by proxy. Under Item 5.02(e), stockholders approved the company's 2025 Equity Incentive Plan (the "2025 Plan") and an amendment and restatement of the 2018 Employee Stock Purchase Plan (the "Amended and Restated ESPP"). The filing incorporates by reference the summary of these plans' material terms in the definitive proxy statement filed with the SEC on April 9, 2025. Stockholders elected four Class II Directors to three-year terms expiring at the 2028 Annual Meeting: Kyle W. Gano, Ph.D., Richard F. Pops, Shalini Sharp, and Stephen A. Sherwin, M.D. Richard F. Pops drew the most votes withheld at 12,809,685, while Kyle W. Gano, Ph.D. drew the fewest at 1,382,673. Class III directors Kevin C. Gorman, Ph.D., Gary A. Lyons, and Johanna Mercier continue until the 2026 meeting, and Class I directors William H. Rastetter, Ph.D., George J. Morrow, Leslie V. Norwalk, and Christine A. Poon continue until the 2027 meeting. The advisory say-on-pay proposal was approved, with 77,981,925 votes for and 6,070,336 against. The 2025 Plan received 72,648,862 votes for and 12,884,104 against, and was approved. The Amended and Restated ESPP received 85,402,588 votes for and 138,042 against, and was approved. Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 85,019,349 votes for and 5,179,700 against. Broker non-votes totaled 4,705,420 on the director, say-on-pay, and 2025 Plan items.
Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2025
Neurocrine Biosciences, Inc. reported a sharp drop in first-quarter 2025 profitability despite growth in revenue. Total revenues were $572.6 million versus $515.3 million a year earlier, driven by INGREZZA net product sales of $545.2 million (versus $506.0 million) and first CRENESSITY net product sales of $14.5 million following its December 2024 launch. However, operating income fell to $23.6 million from $99.3 million, as research and development expense rose to $263.2 million from $159.4 million, largely due to $37.5 million and $7.5 million milestone expenses payable to Takeda and Xenon, and selling, general and administrative expense rose to $276.5 million from $243.1 million. Net income declined to $7.9 million, or $0.08 per diluted share, from $43.4 million, or $0.42 per diluted share, with an unrealized loss of $30.6 million on equity investments also weighing on results. The balance sheet shows total cash, cash equivalents and marketable securities of $1,758.8 million at March 31, 2025, down from $1,815.6 million at December 31, 2024. Operating cash flow was $64.8 million versus $130.3 million a year earlier, and the company repurchased $150.0 million of common stock during the quarter under its 2025 Repurchase Program, leaving $350.0 million available. Stockholders' equity declined to $2,535.7 million, and accumulated deficit moved to $(5.3) million from retained earnings of $29.2 million. The filing also describes ongoing patent litigation: in April 2025 the company sued Zydus entities over a Paragraph IV ANDA filing for a generic INGREZZA SPRINKLE, and in January 2025 it sued Spruce Biosciences. Management stated it believes no pending claims are likely to have a material adverse effect individually or in the aggregate.
Neurocrine Biosciences 8-K Report, Financial Results (May 5, 2025)
Neurocrine Biosciences, Inc. reported first-quarter 2025 results for the period ended March 31, 2025, with total revenues of $572.6 million, up from $515.3 million a year earlier. INGREZZA net product sales were $545.2 million, which the company states represents 8% growth compared with the first quarter of 2024, driven by record new patient starts and improved gross-to-net dynamics. CRENESSITY, in its initial launch, generated net product sales of $14.5 million and 413 total patient enrollment start forms. GAAP net income fell to $7.9 million, or $0.08 per diluted share, from $43.4 million, or $0.42 per diluted share. Non-GAAP net income was $71.5 million, or $0.70 per diluted share, compared with $124.8 million, or $1.20 per diluted share. The decline reflects higher R&D and SG&A expense, including a $45 million development milestone in R&D tied to the start of the osavampator Phase 3 program, and a $31 million loss from changes in fair values of equity investments. The company reaffirmed its 2025 guidance, including INGREZZA net product sales of $2.5 to $2.6 billion, GAAP R&D expense of $960 to $1,010 million, and GAAP SG&A expense of $1,110 to $1,130 million. Management highlighted the initiation of two Phase 3 registrational programs, for osavampator in major depressive disorder and NBI-1117568 in schizophrenia, along with Phase 1 studies for NBI-921355 and NBI-1140675. Total cash, cash equivalents, and marketable securities were $1,758.8 million at March 31, 2025, versus $1,815.6 million at December 31, 2024. The company completed a $300 million accelerated share repurchase on February 5, 2025, and had repurchased $150 million under a second $500 million program, with $350 million remaining. The filing also notes the appointment of Sanjay Keswani, M.D., as Chief Medical Officer effective June 2, 2025, and top-line data from the Phase 4 KINECT-PRO study of INGREZZA in tardive dyskinesia. Management described the combination of INGREZZA and CRENESSITY as a solid foundation for near- and long-term revenue growth.
Neurocrine Biosciences 8-K Report, Executive Changes (Apr 4, 2025)
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) filed this Current Report on Form 8-K on April 4, 2025 to announce a leadership change in its executive team. On April 2, 2025, Sanjay Keswani, M.D. agreed to succeed Eiry W. Roberts, M.D. as Chief Medical Officer, effective June 2, 2025. Dr. Roberts had served as Chief Medical Officer for the past seven years and, as previously announced in July 2023, had decided to retire for personal reasons. She will remain with the Company in a strategic advisory role after the handover. According to the attached press release (Exhibit 99.1), Dr. Keswani has more than 20 years of pharmaceutical industry experience and will lead clinical development and medical affairs. His previous roles include President and CEO of ImmunoBrain, Senior Vice President and R&D Head for Neuroscience, Ophthalmology and Rare Diseases at Hoffman La Roche, and Vice President of Exploratory and Clinical Translational Research at Bristol-Myers Squibb. CEO Kyle W. Gano, Ph.D., said the appointment extends the Company's reach beyond small molecule medicines into new modalities. The press release also credits Dr. Roberts with leading indication expansion for INGREZZA (valbenazine), the crinecerfont program that led to FDA approval of CRENESSITY (crinecerfont), and Phase 2 proof-of-concept studies for osavampator and NBI-1117568, both of which are moving into registrational programs this year.
Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2024
Neurocrine Biosciences, Inc. reported net product sales of $2.33 billion for 2024, up from $1.86 billion in 2023, driven primarily by INGREZZA, which generated $2.31 billion in net product sales and accounted for substantially all product sales. Total revenues were $2.36 billion, operating income was $570.5 million, and net income was $341.3 million, compared with $249.7 million in 2023. Diluted EPS was $3.29. Results were partly offset by $138.4 million of charges associated with the conversion and settlement of the 2024 convertible senior notes and by higher research and development expense of $731.1 million, up from $565.0 million. The company launched CRENESSITY for classic congenital adrenal hyperplasia in December 2024 following FDA approval, and it expanded its pipeline. Osavampator advanced into Phase 3 for major depressive disorder after the company converted its Takeda profit-share arrangement into a royalty-bearing license in January 2025. NBI-1117568 completed Phase 2 in schizophrenia and is expected to enter Phase 3 in the first half of 2025. Cash, cash equivalents and marketable securities totaled $1.82 billion at year-end, and working capital was $1.22 billion. Investors should note the concentration of revenue: four customers represented approximately 93% of total product sales in 2024. The filing also highlights exposure to Medicare drug price negotiation under the Inflation Reduction Act, although INGREZZA qualified for the small biotech exception and the specified small manufacturer discount phase-in. The company completed a $300.0 million accelerated share repurchase in February 2025, and its CEO transitioned from Kevin Gorman to Kyle Gano in October 2024.
Neurocrine Biosciences 8-K Report, Financial Results (Feb 6, 2025)
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported fourth quarter and fiscal 2024 results on February 6, 2025, as furnished under Item 2.02 in Exhibit 99.1. Total revenues for the fourth quarter were $627.7 million, up from $515.2 million, and full-year total revenues were $2,355.3 million, up from $1,887.1 million. INGREZZA fourth-quarter net product sales were $615 million, growing 23%, and fiscal 2024 INGREZZA net product sales were $2.3 billion, growing 26%. CRENESSITY, approved by the FDA in December 2024, generated $2 million in net product sales from initial pharmacy orders. GAAP net income for the fourth quarter was $103.1 million ($1.00 diluted EPS) versus $147.7 million ($1.44) a year earlier, while full-year GAAP net income was $341.3 million ($3.29 diluted EPS) versus $249.7 million ($2.47). Full-year 2024 GAAP results included $138.4 million of charges associated with convertible senior notes and $71.7 million of collaboration development milestone expense. The company guided 2025 INGREZZA net product sales to $2.5 to $2.6 billion, with GAAP R&D expense of $960 to $1,010 million and GAAP SG&A expense of $1,110 to $1,130 million. Guidance includes initiation of Phase 3 programs for osavampator in major depressive disorder and NBI-568 in schizophrenia in the first half of 2025, along with $60 million of expected development milestone expense. Cash, cash equivalents and marketable securities totaled approximately $1.8 billion at December 31, 2024, and the company completed a $300 million accelerated share repurchase in early February 2025, retiring approximately 2.3 million shares in total. Other developments included CMS notification that INGREZZA qualifies for the small biotech exemption under the Medicare Drug Price Negotiation Program, and an amended Takeda collaboration under which Neurocrine will hold exclusive rights to osavampator worldwide except Japan, where Takeda will hold exclusive rights. The company also initiated a Phase 1 study of NBI-921355 for epilepsy and reported KINECT-HD and tardive dyskinesia data for INGREZZA.
Neurocrine Biosciences 8-K Report, Material Agreement (Jan 27, 2025)
On January 24, 2025, Neurocrine Biosciences, Inc. entered into an Amended and Restated Exclusive License Agreement with Takeda Pharmaceutical Company Limited, which amends and restates in its entirety the Exclusive License Agreement dated June 12, 2020. The amendment converts the arrangement for osavampator (NBI-1065845 / TAK-653), a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder, from a shared operating profit and loss structure to a royalty-bearing license. Neurocrine will hold exclusive worldwide development and commercialization rights to osavampator for all indications, excluding Japan, where Takeda will reacquire exclusive rights. Each party will bear development costs in its own territory and is eligible to receive royalties on the other party's net sales in that territory. Takeda is now eligible for development and commercial milestones, as contemplated in the original agreement. The filing also states that the company previously terminated the DAAO inhibitors under the original agreement, including luvadaxistat, and the GPR139 agonists, including NBI-1070770 (listed as NBI-1065846 in the filing). Neurocrine stated that, upon successful development and commercialization of osavampator, it expects tiered royalties payable to Takeda in the mid-to-upper teens in the United States and low double-digits outside the United States, on a blended basis as a percentage of net sales. The company would also be entitled to royalties from Takeda on net sales in Japan. Neurocrine's CEO, Kyle Gano, Ph.D., said the company had completed its End-of-Phase 2 meeting with the FDA for osavampator and expects to begin the Phase 3 program in the first half of 2025. The full agreement will be filed as an exhibit to the company's Form 10-Q for the period ending March 31, 2025, with confidential terms redacted. The Regulation FD press release announcing the agreement is furnished as Exhibit 99.1.
Neurocrine Biosciences 8-K Report, Corporate Update (Dec 20, 2024)
On December 20, 2024, Neurocrine Biosciences, Inc. filed a Form 8-K under Item 8.01 (Other Events) announcing that CRENESSITY (crinecerfont) capsules and oral solution are now available in the United States. The drug was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH). The filing attaches a press release (Exhibit 99.1) describing CRENESSITY as a first-in-class oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist. The Company has set a wholesale acquisition cost of approximately $38,333 for a 30-day supply in the United States, and approximately $19,167 for a 30-day supply for pediatric patients weighing less than 20 kilograms. The Company expects 90% of patients will have a monthly copay of $12 or less. Access is centralized through PANTHERx Rare, a specialty pharmacy, and the Company offers a free patient assistance program, Neurocrine Access Support. The filing's forward-looking statements flag risks including adequate third-party reimbursement, the Company's dependence on third parties for development and manufacturing, and the commercialization of CRENESSITY. The press release states that the approval was supported by the CAHtalyst Pediatric study (103 patients aged four to 17) and the CAHtalyst Adult study (182 patients aged 18 to 58), and that the open-label extension portions of both studies are ongoing.
Neurocrine Biosciences 8-K Report, Corporate Update (Nov 1, 2024)
Neurocrine Biosciences, Inc. reported in this Form 8-K, filed November 1, 2024, that on October 31, 2024 it entered into an accelerated share repurchase (ASR) agreement with Goldman Sachs & Co. LLC to repurchase $300.00 million of its common stock. The ASR is being completed under a previously announced $300.00 million share repurchase program authorized by the Board of Directors. Under the ASR Agreement, the company will pay the $300.00 million Repurchase Price on November 4, 2024 and receive common stock with an aggregate value equal to 80% of that price, based on the October 31, 2024 closing share price. The final number of shares will be based on volume-weighted average prices over the transaction term, less a discount, subject to adjustments. At final settlement, Neurocrine may receive additional shares from Goldman Sachs or, in certain circumstances, may have to deliver shares or make a cash payment at its option. The ASR agreement includes customary provisions, including adjustment, acceleration, extension and early termination terms, along with representations and warranties. The transaction is scheduled to terminate in the first quarter of 2025.
Neurocrine Biosciences 8-K Report, Financial Results (Oct 30, 2024)
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported third quarter 2024 results on October 30, 2024, per Exhibit 99.1 to this Form 8-K. Third quarter total revenues were $622.1 million, versus $498.8 million in the third quarter of 2023, with net product sales of $616.6 million. INGREZZA third quarter net product sales were $613 million, growing 26% year over year, driven by underlying patient demand and improved gross-to-net dynamics. GAAP net income was $129.8 million, or $1.24 per diluted share, compared with $83.1 million, or $0.82, a year earlier. Non-GAAP net income was $189.2 million, or $1.81 per diluted share. Cash, cash equivalents and marketable securities totaled $1,871.9 million at September 30, 2024. The company raised its 2024 INGREZZA net product sales guidance to $2.30 to $2.32 billion and updated its expense guidance. GAAP R&D is now expected at $700 to $720 million and GAAP SG&A at $970 to $990 million. Management cited investments in R&D, the expanded psychiatry and long-term care sales teams, and pre-launch activities for crinecerfont, which has a Priority Review from the FDA in congenital adrenal hyperplasia. The Board authorized a $300 million share repurchase plan, and the company intends to enter a $300 million accelerated share repurchase transaction in the coming days, subject to market conditions. The filing also discloses pipeline and leadership developments. Kyle W. Gano, Ph.D. became Chief Executive Officer effective October 11, 2024. The Phase 2 study of NBI-1117568, an M4 agonist for schizophrenia, was positive and triggered a $35 million milestone payment to Nxera, with Phase 3 initiation expected in the first half of 2025. The luvadaxistat Phase 2 ERUDITE study missed its primary endpoint, and the company has given notice to terminate that license with Takeda, effective April 2025.
Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2024
Neurocrine Biosciences, Inc. reported third-quarter 2024 results in its Form 10-Q for the period ended September 30, 2024. Net product sales were $616.6 million for the quarter, up from $491.8 million a year earlier, and INGREZZA net product sales were $612.9 million. Net income rose to $129.8 million from $83.1 million, and diluted EPS was $1.24 versus $0.82. For the first nine months, total revenues were $1,727.6 million and net income was $238.2 million, compared with $102.0 million in the prior-year period. Nine-month results were affected by $138.4 million of charges tied to the May 2024 settlement of the 2024 convertible senior notes, and by $14.0 million of impairment charges on vacated leased office space. Leadership and pipeline developments were significant during the quarter. Kevin Gorman, Ph.D., retired as CEO effective October 11, 2024, and Kyle Gano, Ph.D., succeeded him and joined the Board. The company announced positive Phase 2 topline data for NBI-1117568 in schizophrenia and for NBI-1065845 in major depressive disorder, and FDA accepted NDAs for crinecerfont in classic congenital adrenal hyperplasia with PDUFA dates of December 29 and December 30, 2024. The Phase 2 study of luvadaxistat did not meet its primary endpoint, and the company gave notice to terminate its license agreements with Takeda and Idorsia. At September 30, 2024, cash, cash equivalents and marketable securities totaled $1,871.9 million, and working capital was $1,446.9 million. In October 2024 the Board authorized a share repurchase program of up to $300 million, to be executed through an accelerated share repurchase transaction subject to market conditions. The filing states that existing capital resources are sufficient for at least the next 12 months.
Neurocrine Biosciences 8-K Report, Executive Changes (Oct 11, 2024)
Neurocrine Biosciences, Inc. filed this Form 8-K under Item 5.02 to disclose an Amended and Restated Employment Agreement with Kyle Gano, Ph.D., entered into on October 11, 2024, in connection with a previously announced leadership transition. Under the agreement, Dr. Gano becomes President and Chief Executive Officer effective October 11, 2024, with an annual base salary of $900,000 and an initial target annual cash incentive bonus equal to 100% of base pay earned for the applicable year. Dr. Gano will receive promotion equity grants under the 2020 Equity Incentive Plan, as amended: stock options with a target grant value of approximately $750,000 vesting in equal monthly installments over four years, restricted stock units with a target grant value of approximately $300,000 vesting in equal annual installments over four years, and performance-vesting restricted stock units with a target grant value of approximately $450,000 vesting under the terms of the March 2024 executive PRSU grants. These grants are scheduled to be made automatically two business days after the filing of the company's first Form 10-Q following the Effective Date, provided he remains employed, with share numbers set by the grant-date stock price. The agreement also sets severance terms. Outside a change in control determination period (from a change in control through 12 months after), a termination without cause or resignation for good reason triggers 1.5 times the sum of base salary and target bonus, a pro rata actual bonus, up to 18 months of health premiums, and vesting over a 15-month period, with discretionary vesting of performance awards. Within that period, the multiple rises to 2 times, with a pro rata target bonus, up to 24 months of health premiums, and full equity vesting, with performance awards vesting at the greater of target or actual. Death or disability triggers full equity vesting. The full agreement will be filed as an exhibit to a subsequent SEC filing.
Neurocrine Biosciences 8-K Report, Regulation FD Disclosure (Aug 28, 2024)
Neurocrine Biosciences, Inc. reported positive top-line data from its Phase 2 NBI-'568-SCZ2028 dose-finding study of NBI-'568 (NBI-1117568) in adults with schizophrenia experiencing an acute exacerbation or relapse. The once-daily 20 mg dose met the primary endpoint, with a placebo-adjusted mean reduction of 7.5 points in PANSS total score at Week 6 (p=0.011, effect size 0.61) and an 18.2-point reduction from baseline. The 20 mg dose also showed statistically significant improvements on CGI-S and Marder Factor Scores for positive and negative symptoms. The 40 mg once-daily, 60 mg once-daily, and 30 mg twice-daily arms did not reach statistical significance on the primary endpoint versus placebo (p=0.282, p=0.189, and p=0.090, respectively). The company stated that NBI-'568 was generally safe and well tolerated at all doses studied. Treatment discontinuation rates due to adverse events were 5.0% across all NBI-'568 arms versus 4.3% for placebo, according to the slide presentation. The most common adverse events were somnolence, dizziness, and headache. Gastrointestinal events, cardiovascular-related events, and extrapyramidal symptoms were reported at low frequency, and NBI-'568 was not associated with greater weight gain than placebo. Neurocrine expects to advance NBI-'568 into Phase 3 development in schizophrenia in early 2025. The filing describes NBI-'568 as the first investigational, oral, muscarinic M4 selective agonist in development for schizophrenia. Neurocrine also noted a broader muscarinic portfolio, including NBI-1117567, NBI-1117569, and NBI-1117570, which it acquired from Nxera Pharma (formerly Sosei Heptares), and NBI-1076986, an internally developed M4 antagonist. The filing includes forward-looking statement cautions noting that top-line data may change after more comprehensive review.
Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2024
Neurocrine Biosciences, Inc. reported its Form 10-Q for the quarter ended June 30, 2024. Net product sales were $583.8 million for the second quarter of 2024 versus $446.3 million a year earlier, driven by INGREZZA net product sales of $579.5 million. Total revenues were $590.2 million and net income was $65.0 million, or $0.63 per diluted share, compared with $95.5 million, or $0.95 per diluted share, in the second quarter of 2023. For the first six months of 2024, net income was $108.4 million, versus $18.9 million a year earlier, which included $143.9 million of acquired in-process R&D expense tied to the Voyager expansion. The six-month 2024 results also reflected $138.4 million of charges associated with conversions of the 2024 convertible senior notes upon their May 2024 maturity, which were settled in cash for $308.8 million. Research and development expense rose to $191.1 million in the second quarter from $145.8 million, and SG&A rose to $242.0 million from $221.8 million, reflecting commercial investment, pre-launch crinecerfont activities, and a $14.0 million impairment charge on vacated leased office space. Cash and cash equivalents were $139.7 million and total cash, cash equivalents and marketable securities were $1,676.7 million at June 30, 2024. Stockholders' equity increased to $2,509.2 million from $2,232.0 million at year-end 2023, and the company stated its existing resources are sufficient for at least the next 12 months. The filing also discloses a planned CEO transition, with Kevin Gorman retiring on October 11, 2024 and Kyle Gano succeeding him, and FDA acceptance of NDAs with Priority Review for crinecerfont for classic congenital adrenal hyperplasia, with PDUFA target dates of December 29, 2024 and December 30, 2024. Management notes that INGREZZA's qualification as a specified small manufacturer under the Medicare Part D discount program may phase in discounts, and that the overall impact on INGREZZA revenues is inherently uncertain.
Neurocrine Biosciences 8-K Report, Financial Results (Aug 1, 2024)
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported second quarter 2024 results on August 1, 2024, as furnished under Item 2.02 of this Form 8-K (Exhibit 99.1 press release). Total revenues for the quarter were $590.2 million, up from $452.7 million in the second quarter of 2023, with net product sales of INGREZZA at $583.8 million (the press release describes INGREZZA second quarter net sales as $580 million, growing 32% year over year). GAAP net income was $65.0 million, or $0.63 per diluted share, versus $95.5 million, or $0.95 per diluted share, a year earlier. Non-GAAP net income was $168.9 million, or $1.63 per diluted share, compared with $125.7 million, or $1.25, in the prior-year quarter. GAAP results were affected by a $49.7 million charge tied to convertible senior notes conversion settlements, a $19.9 million loss on equity security investments, $27 million of development milestones expensed under collaborations, and a $14 million leased office impairment. The company raised its 2024 INGREZZA net product sales guidance to $2.25 billion to $2.3 billion. Updated 2024 expense guidance calls for GAAP R&D of $665 million to $695 million, non-GAAP R&D of $600 million to $630 million, GAAP SG&A of $955 million to $975 million, and non-GAAP SG&A of $830 million to $850 million. Cash, cash equivalents and marketable securities totaled approximately $1.7 billion at June 30, 2024 ($1,676.7 million), after a $309 million payment to fully retire the convertible senior notes. Leadership news is significant: CEO Kevin Gorman, Ph.D. will retire on October 11, 2024, and Kyle Gano, Ph.D., currently Chief Business Development and Strategy Officer, will succeed him and join the Board. The company also reported positive topline Phase 2 SAVITRI data for NBI-1065845 in major depressive disorder, FDA acceptance and Priority Review for crinecerfont in congenital adrenal hyperplasia with PDUFA dates of December 29 and 30, 2024, and Phase 2 top-line data for NBI-1117568 and luvadaxistat expected in Q3 2024.
Neurocrine Biosciences 8-K Report, Executive Changes (May 28, 2024)
On May 28, 2024, Neurocrine Biosciences, Inc. ("Neurocrine") announced that Kevin C. Gorman, Ph.D. will retire as President and Chief Executive Officer effective October 11, 2024 (the "Transition Date"). Dr. Gorman notified the company of his planned retirement on May 24, 2024, and will remain on the Board of Directors as a member. The company also announced that Kyle Gano, Ph.D., age 51, will succeed him as President and Chief Executive Officer effective on the Transition Date. Dr. Gano will also join the Board as a Class II director, to serve until the 2025 annual meeting of stockholders. The filing states that he has served as Chief Business Development Officer since 2011 and as Chief Business Development and Strategy Officer since 2020, with responsibility for all business and corporate development activities, including collaborations with AbbVie, Mitsubishi Tanabe Pharma, Takeda, Xenon Pharmaceuticals, Voyager Therapeutics, and others. He joined Neurocrine in 2001. Effective on the Transition Date, the Board amended Section 3.2 of the Bylaws to increase the authorized size of the Board from ten to eleven members, with the new seat filled by Dr. Gano's appointment. The amendment is filed as Exhibit 3.1.
Neurocrine Biosciences 8-K Report, Executive Changes (May 23, 2024)
Neurocrine Biosciences, Inc. filed this Form 8-K on May 23, 2024 to report the results of its 2024 Annual Meeting of Stockholders, held on May 22, 2024. Stockholders approved an amendment to the Company's 2020 Equity Incentive Plan (the Amended 2020 Plan), and the summary of its material terms is set forth in the definitive proxy statement filed with the SEC on April 10, 2024. Of the 100,580,497 shares of common stock entitled to vote as of the March 25, 2024 record date, 90,166,107 shares were present in person or by proxy. Stockholders voted on four matters. All four nominees for Class I Director (William H. Rastetter, Ph.D., George J. Morrow, Leslie V. Norwalk, and Christine A. Poon) were elected to three-year terms expiring at the 2027 Annual Meeting. The advisory vote on named executive officer compensation passed with 80,281,842 votes for and 4,276,395 against. The Amended 2020 Plan was approved with 76,076,416 votes for and 9,499,523 against. The appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2024 was ratified with 84,641,389 votes for and 5,451,051 against. For investors, the filing is primarily governance-related and reports no new financial results, transactions, or changes in leadership beyond the director elections. The most notable item is the approval of the Amended 2020 Plan, which the Company describes only by reference to its proxy statement, and the Plan's specific terms are not stated in this filing.
Neurocrine Biosciences 8-K Report, Financial Results (May 1, 2024)
Neurocrine Biosciences, Inc. reported first quarter 2024 results in a press release furnished under Item 2.02 of this Form 8-K (Exhibit 99.1). Total revenues were $515.3 million, up from $420.4 million in the first quarter of 2023, with net product sales of $509.0 million. INGREZZA first quarter net product sales were $506 million, which the company said grew 23% year over year, driven by strong underlying patient demand and improved gross-to-net dynamics. GAAP net income was $43.4 million, or $0.42 per diluted share, compared with a GAAP net loss of $76.6 million, or $0.79 per share, in the prior-year quarter. Non-GAAP net income was $124.8 million, or $1.20 per diluted share. The first quarter 2024 GAAP results include an $89 million charge tied to the company's election to settle its convertible senior notes in cash. The company reaffirmed its 2024 INGREZZA net product sales guidance of $2,100 million to $2,200 million and updated its expense guidance, with GAAP R&D expense of $665 million to $695 million and GAAP SG&A expense of $920 million to $940 million. GAAP R&D guidance includes approximately $34 million of development milestone expense tied to collaborations. Cash, cash equivalents and marketable securities totaled $1,911.0 million at March 31, 2024, compared with $1,719.1 million at December 31, 2023. Pipeline progress included the April 2024 submission of two New Drug Applications to the FDA for crinecerfont in adult and pediatric classic congenital adrenal hyperplasia, FDA approval of INGREZZA SPRINKLE capsules on April 30, 2024, and positive Phase 2 top-line data for NBI-1065845 in major depressive disorder, where the company is engaging with the FDA on a path forward. The company also expects top-line Phase 2 data for NBI-1117568 and luvadaxistat in the third quarter of 2024.
Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2024
Neurocrine Biosciences, Inc. reported first-quarter 2024 results in its Form 10-Q filed May 1, 2024, with net product sales of $509.0 million, up from $415.3 million in the prior-year quarter, driven primarily by INGREZZA net product sales of $506.0 million, which the filing attributes to strong underlying patient demand and improved gross-to-net dynamics. Total revenues were $515.3 million versus $420.4 million, and the company posted net income of $43.4 million, or $0.42 per diluted share, compared with a net loss of $76.6 million in the first quarter of 2023. Results were affected by $88.7 million of charges tied to the bifurcation of the embedded conversion option of the 2.25% convertible senior notes due May 15, 2024, which the company elected to settle in cash. Acquired in-process R&D fell to $6.0 million from $143.9 million, and operating income was $99.3 million versus an operating loss of $114.2 million. The balance sheet strengthened, with total cash, cash equivalents and marketable securities of $1.91 billion at March 31, 2024, up from $1.72 billion at December 31, 2023, and operating cash flow of $130.3 million. The company stated that existing resources are sufficient for at least the next 12 months and that it has sufficient cash to repay the $170.4 million of remaining 2024 Notes at maturity. Business highlights for April 2024 included positive Phase 2 data for NBI-1065845 in major depressive disorder, two New Drug Applications submitted to the FDA for crinecerfont in classic congenital adrenal hyperplasia, and FDA approval of INGREZZA SPRINKLE. The filing also notes that the company was notified by CMS in April 2024 that it qualified as a "specified small manufacturer" under the Medicare Part D manufacturer discount program, which will phase in the discount. The filing highlights concentration and reimbursement risks: four specialty pharmacy customers represented approximately 94% of total product sales in the quarter, and a majority of current revenue is derived from federal healthcare programs including Medicare and Medicaid. The company's potential future collaboration milestone payments total approximately $17.5 billion across its existing agreements, and it reported 1,448 full-time employees as of March 31, 2024.
Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported total revenues of $1,887.1 million for 2023, up from $1,488.7 million in 2022, driven by net product sales of $1,860.6 million. INGREZZA net product sales totaled $1.8 billion in 2023 (about 99% of total net product sales), reflecting higher prescription demand, continued direct-to-consumer advertising and the expansion of the sales force completed in April 2022. Net income rose to $249.7 million ($2.47 diluted EPS) from $154.5 million in 2022, while operating income was $250.9 million. Operating expenses increased, with research and development at $565.0 million and SG&A at $887.6 million, and acquired in-process R&D of $143.9 million tied to the Voyager collaboration. The balance sheet strengthened, with cash, cash equivalents and marketable securities of $1,719.1 million at December 31, 2023, versus $1,288.7 million a year earlier. Operating cash flow was $389.9 million. The company's convertible senior notes due May 2024 had $170.4 million principal outstanding, and the company elected to settle conversions in cash. The accumulated deficit narrowed to $157.1 million. The company also reported Phase 3 positive top-line data for crinecerfont in adult and pediatric congenital adrenal hyperplasia, with NDA submissions expected in the second quarter of 2024, and settled all patent litigation over INGREZZA generics, with generic entry permitted beginning March 1, 2038, or earlier under certain circumstances. Key risks in the filing include reliance on a limited number of customers (four customers represented approximately 91% of 2023 product sales), dependence on federal healthcare program payors including Medicare and Medicaid, the Inflation Reduction Act's drug price negotiation provisions, reliance on third-party contract manufacturers, and the cost of pipeline programs that did not meet primary endpoints in the fourth quarter of 2023.
Neurocrine Biosciences 8-K Report, Financial Results (Feb 7, 2024)
Neurocrine Biosciences, Inc. reported fourth-quarter and full-year 2023 results on February 7, 2024, with INGREZZA (valbenazine) driving growth. Fourth-quarter total revenues were $515.2 million, and full-year total revenues were $1,887.1 million, compared with $1,488.7 million in 2022. INGREZZA net product sales were $500 million in the fourth quarter, up 25% year over year, and $1.84 billion for the full year, up 29%. Full-year GAAP net income was $249.7 million, or $2.47 per diluted share, versus $154.5 million, or $1.56 per diluted share, in 2022. Full-year non-GAAP net income was $390.0 million, or $3.86 per diluted share. Cash, cash equivalents and marketable securities totaled $1,719.1 million at December 31, 2023. For 2024, the company guided to INGREZZA net product sales of $2.1 billion to $2.2 billion, GAAP R&D expense of $645 million to $675 million, and GAAP SG&A expense of $930 million to $950 million. The guidance also states that SG&A reflects pre-launch commercial activities for crinecerfont. The company expects to submit a New Drug Application for crinecerfont to the FDA in the second quarter of 2024, following positive Phase 3 results in congenital adrenal hyperplasia. Crinecerfont received Breakthrough Therapy designation in December 2023. A PDUFA date of April 30, 2024 is listed for the sprinkle formulation of valbenazine. Recent developments include the resolution of all patent litigation against companies that filed ANDAs for generic versions of INGREZZA. Those companies may sell generic versions beginning March 2038, or earlier under certain circumstances. The filing also lists a series of 2024 pipeline milestones, including Phase 2 data readouts for several programs in the first and second halves of 2024.
Neurocrine Biosciences 8-K Report, Corporate Update (Nov 13, 2023)
On November 10, 2023, Neurocrine Biosciences, Inc. entered into an agreement with Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Limited (collectively, "Zydus") to resolve patent litigation over INGREZZA®, the Company's medication for tardive dyskinesia and chorea associated with Huntington's disease. The litigation arose after Zydus notified the Company that it had submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market generic versions of INGREZZA before the expiration of the Company's Orange Book listed patents. Under the agreement, the Company has granted Zydus the right to sell generic INGREZZA in the United States beginning October 1, 2038, or earlier under certain circumstances. The Company previously reached similar settlements with Sandoz Inc. and Crystal Pharmaceutical (Suzhou) Co., Ltd. and Crystal Pharmatech Co., Ltd. (the "Sandoz Parties"), Teva Pharmaceuticals entities, and Lupin Limited and Lupin Pharmaceuticals, Inc. Those agreements give Teva, the Sandoz Parties, and Lupin the right to sell generic INGREZZA beginning March 1, 2038, or earlier under certain circumstances. The Company states that the settlements with Teva, the Sandoz Parties, Lupin, and Zydus together resolve all patent litigation it brought against companies that filed ANDAs seeking to market generic INGREZZA. The filing states that the Zydus Agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice, as required by law. The filing does not include any financial results, revenue figures, or financial projections.
Neurocrine Biosciences 8-K Report, Corporate Update (Nov 9, 2023)
Neurocrine Biosciences, Inc. disclosed in a Current Report on Form 8-K (Item 8.01, Other Events) that on November 9, 2023 it entered into an agreement with Lupin Limited and Lupin Pharmaceuticals, Inc. (together, "Lupin") to resolve patent litigation over INGREZZA, its medication for tardive dyskinesia and chorea associated with Huntington's disease. The litigation had been filed by the Company in the U.S. District Court for the District of Delaware after Lupin notified it of an Abbreviated New Drug Application (ANDA) seeking approval to market generic INGREZZA before the expiration of Orange Book-listed patents. Under the settlement, the Company has granted Lupin the right to sell generic versions of INGREZZA in the United States beginning March 1, 2038, or earlier under certain circumstances. The agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice, as required by law. The filing also states that similar patent litigation against the remaining company that filed an ANDA for generic INGREZZA remains pending, with a trial date set for January 2, 2024. The filing notes that the Company previously settled similar litigation with Sandoz Inc. and Crystal Pharmaceutical (Suzhou) Co., Ltd. and Crystal Pharmatech Co., Ltd. (together, the "Sandoz Parties") and with Teva Pharmaceuticals entities. Each of Teva and the Sandoz Parties also has the right to sell generic INGREZZA in the United States beginning March 1, 2038, or earlier under certain circumstances, so the Lupin settlement aligns generic entry timing across the settled challengers.
Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2023
Neurocrine Biosciences, Inc. reported third-quarter 2023 total revenues of $498.8 million, up from $387.9 million in the year-earlier quarter, driven by net product sales of $491.8 million, primarily INGREZZA net product sales of $485.7 million on higher prescription demand and increased commercial activities. Net income for the quarter was $83.1 million, compared with $68.5 million a year earlier, and diluted EPS was $0.82 versus $0.69. For the first nine months of 2023, net income was $102.0 million, which included a $143.9 million acquired in-process research and development charge tied to the upfront fee under the expanded Voyager Therapeutics partnership. Total revenues for the nine months were $1,371.9 million. The balance sheet remained strong, with total cash, cash equivalents and marketable securities of $1,549.8 million at September 30, 2023, against total current liabilities of $691.6 million and total stockholders' equity of $2,002.1 million. Management states that existing capital resources, anticipated INGREZZA sales and investment income will be sufficient to fund requirements for at least the next 12 months. The 2024 convertible senior notes, with $170.4 million principal outstanding, became convertible at holders' option from October 1, 2023 through December 29, 2023 because the conditional conversion feature was triggered; the company would settle the principal in cash. Key pipeline and regulatory events in the period included FDA approval of INGREZZA for chorea associated with Huntington's disease in August 2023, FDA acceptance of the INGREZZA oral granules NDA with a PDUFA target date of April 30, 2024, and positive Phase III CAHtalyst top-line data for crinecerfont in adults (September 2023) and pediatrics (October 2023) with classic congenital adrenal hyperplasia. The company also disclosed ongoing ANDA patent litigation over INGREZZA, with trial scheduled for January 2, 2024, and that four customers accounted for approximately 91% of total product revenue for the nine months.
Neurocrine Biosciences 8-K Report, Financial Results (Oct 31, 2023)
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported third quarter 2023 results for the period ended September 30, 2023, and raised its 2023 INGREZZA net product sales guidance to $1.82 billion to $1.84 billion. INGREZZA third quarter net product sales were $486 million, growing 29% year over year on prescription demand. Total revenues for the quarter were $498.8 million, compared with $387.9 million in the third quarter of 2022. GAAP net income was $83.1 million, or $0.82 per diluted share, versus $68.5 million, or $0.69 per diluted share, a year earlier. Non-GAAP net income was $156.1 million, or $1.54 per diluted share, compared with $106.7 million, or $1.08 per diluted share. The company cited higher R&D spending on its expanded clinical portfolio and higher SG&A spending on INGREZZA commercial initiatives, including the new Huntington's disease chorea indication. The company reported cash, cash equivalents and marketable securities of approximately $1.5 billion at September 30, 2023. Updated 2023 guidance includes GAAP R&D expense of $560 million to $570 million, GAAP SG&A expense of $870 million to $890 million, and acquired in-process R&D of $144 million, which includes $143.9 million associated with a new strategic collaboration with Voyager. The filing also notes positive Phase 3 CAHtalyst top-line results for crinecerfont in adults (September 2023) and pediatric patients (October 2023) with congenital adrenal hyperplasia, and an Analyst Day in New York City on December 5, 2023.
Neurocrine Biosciences 8-K Report, Corporate Update (Oct 6, 2023)
Neurocrine Biosciences, Inc. reported in an 8-K filed October 6, 2023 that on October 5, 2023 it entered into an agreement with Sandoz Inc. and Crystal Pharmaceutical (Suzhou) Co., Ltd. and Crystal Pharmatech Co., Ltd. (together, the "Sandoz Parties") resolving patent litigation over INGREZZA, its medication for tardive dyskinesia and chorea associated with Huntington's disease. The litigation had been filed by the Company in the U.S. District Court for the District of Delaware after the Sandoz Parties notified the Company that they had submitted an Abbreviated New Drug Application (ANDA) to the FDA seeking approval to market generic versions of INGREZZA before expiration of the Company's Orange Book listed patents. Under the settlement, the Company has granted the Sandoz Parties the right to sell generic versions of INGREZZA in the United States beginning February 1, 2040, or earlier under certain circumstances. The agreement must be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice, as required by law. Similar patent litigation against the two remaining companies that filed ANDAs for generic INGREZZA remains pending, with a trial date set for January 2, 2024. For investors, the key items are the defined generic entry date under the Sandoz settlement and the open litigation with the other two ANDA filers.
Neurocrine Biosciences 8-K Report, Corporate Update (Oct 5, 2023)
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) filed this Form 8-K on October 5, 2023 under Item 8.01 (Other Events) to furnish a press release announcing top-line results from the Phase 3 CAHtalyst Pediatric Study of crinecerfont in children and adolescents (ages 2–17) with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The study met its primary endpoint, showing a statistically significant decrease in serum androstenedione from baseline at Week 4 versus placebo (p = 0.0002), and met a key secondary endpoint: a statistically significant percent reduction in daily glucocorticoid (GC) dose while maintaining androgen control at Week 28 versus placebo (p < 0.0001). Approximately 30% of crinecerfont-treated participants achieved a reduction to a physiologic GC dose while maintaining androgen control, compared with 0% on placebo. The company also reported a statistically significant decrease in serum 17-hydroxyprogesterone at Week 4 (p < 0.0001). The company stated that crinecerfont was generally well tolerated, with the most common adverse events being headache, fever, vomiting, upper respiratory tract infection, and nasopharyngitis, few serious adverse events, and none assessed as related to crinecerfont. Completion of the 28-week double-blind period exceeded 95%. Management cited the results, together with the CAHtalyst Adult study results reported the previous month, as supporting crinecerfont's potential as a new standard of care that reduces androgen levels through a non-glucocorticoid mechanism. The company said data from both CAHtalyst studies, including open-label periods, will support regulatory submissions to the FDA in 2024 and later to the European Medicines Agency, with further detail planned for the December 2023 Analyst Day and a peer-reviewed journal publication. The filing notes that top-line data may change following a more comprehensive review.
Neurocrine Biosciences 8-K Report, Corporate Update (Sep 12, 2023)
Neurocrine Biosciences, Inc. filed this Form 8-K on September 12, 2023 under Item 8.01 (Other Events) to announce top-line results from the Phase 3 CAHtalyst Adult Study of crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The attached press release (Exhibit 99.1) states that the study met its primary endpoint at Week 24, showing a statistically significant percent reduction in daily glucocorticoid dose versus placebo while maintaining androgen control (p-value <0.0001). The company also reported a statistically significant decrease in androstenedione at Week 4 versus placebo and a higher share of patients reaching a physiologic glucocorticoid dose at Week 24 (approximately 63% on crinecerfont versus approximately 18% on placebo). The filing states that crinecerfont was generally well tolerated, with the most common adverse events being fatigue, headache, and coronavirus infection, and none of the few serious adverse events assessed as related to crinecerfont. The study enrolled 182 patients and is followed by one year of open-label treatment. Management stated that these data, together with open-label period data, will support regulatory submissions to the U.S. FDA in 2024 and to the European Medicines Agency afterward. Data from the separate CAHtalyst Pediatric Study are expected in early Q4 2023, as planned. For investors, the key takeaways are the positive primary and key secondary endpoint results, the company's stated regulatory timeline, and the upcoming pediatric data readout. The press release notes that additional detail would be presented at the Morgan Stanley 21st Annual Global Healthcare Conference and that further data will be provided in a peer-reviewed journal or at a medical conference at a later date.
Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2023
Neurocrine Biosciences, Inc. reported its Form 10-Q for the quarter ended June 30, 2023. Total revenues were $452.7 million for the second quarter of 2023, up from $378.2 million a year earlier, driven by net product sales of $446.3 million, mainly from INGREZZA ($439.7 million). Net income for the quarter was $95.5 million, or $0.95 per diluted share, compared with a net loss of $16.9 million in the second quarter of 2022. For the first six months of 2023, the company recorded an operating loss of $40.6 million, which reflects $143.9 million of acquired in-process R&D expense tied to the upfront payment under the expanded Voyager Therapeutics partnership. Net income for the six months was $18.9 million. At June 30, 2023, the company reported total cash, cash equivalents and marketable securities of $1,319.3 million, versus $1,288.7 million at December 31, 2022. Cash flows from operating activities were $54.4 million for the six months, compared with $97.6 million a year earlier. Stockholders' equity rose to $1,853.0 million, and $170.4 million of 2.25% convertible senior notes due May 2024 remained outstanding. Management states that existing capital resources and anticipated INGREZZA sales and investment income will be sufficient to meet funding requirements for at least the next 12 months. The filing also describes ongoing ANDA patent litigation in the District of Delaware over generic versions of INGREZZA, with trial scheduled for January 2, 2024. It discloses that the company has given notice to terminate its ONGENTYS license with BIAL, effective in December 2023 as anticipated. Collaboration milestones tied to partners could total up to $16.9 billion, including up to $6.1 billion for the 2023 Voyager Agreement.
Neurocrine Biosciences 8-K Report, Financial Results (Aug 1, 2023)
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported financial results for the second quarter ended June 30, 2023, and raised its 2023 INGREZZA net product sales guidance to $1.77 - $1.82 billion, according to the press release attached as Exhibit 99.1 to this Form 8-K filed August 1, 2023. Second quarter net product sales were $446.3 million on total revenues of $452.7 million, versus $378.2 million in the prior-year quarter. INGREZZA second quarter net product sales were $440 million, growing 26% year over year, driven by prescription demand, and the company cited a record number of new patients receiving therapy during the quarter. GAAP net income for the second quarter of 2023 was $95.5 million, or $0.95 per diluted share, compared with a GAAP net loss of $16.9 million, or $0.18 per share, in the second quarter of 2022, which included a $70.0 million loss on extinguishment of debt. Non-GAAP net income was $125.7 million, or $1.25 per diluted share, versus $82.1 million, or $0.84 per share, a year earlier. Cash, cash equivalents and marketable securities were $1,319.3 million at June 30, 2023 (the balance sheet table shows $976.7 million in cash, cash equivalents and marketable securities, with additional debt securities classified separately). Looking ahead, management highlighted a PDUFA date of August 20, 2023 for valbenazine in chorea associated with Huntington's disease and four pipeline read-outs expected in the fourth quarter of 2023, including Phase 3 registrational data for crinecerfont in pediatric and adult congenital adrenal hyperplasia. Reaffirmed 2023 GAAP R&D guidance is $550-$580 million and GAAP SG&A guidance is $850-$870 million. The filing states that the information is furnished and not deemed filed under Section 18 of the Exchange Act.
Neurocrine Biosciences 8-K Report, Executive Changes (Jul 13, 2023)
Neurocrine Biosciences, Inc. (the Company) filed this Current Report on Form 8-K dated July 13, 2023 under Item 5.02, disclosing a leadership transition. On July 10, 2023, Eiry W. Roberts, M.D. notified the Company of her decision to retire in 2025 from her position as Chief Medical Officer. Dr. Roberts has not yet set her last day of employment and will remain in the role until her replacement has been onboarded. The Company has initiated a search for a replacement Chief Medical Officer. According to the filing, Dr. Roberts is retiring for personal reasons and not because of any disagreement with the Company on matters relating to its operations, policies or practices. The filing is largely procedural. It contains standard forward-looking statements, including those covering Dr. Roberts' retirement plans and the search for a successor, and refers readers to the risk factors in the Company's Form 10-Q for the quarter ended March 31, 2023.